In one more example, Qure.ai Technologies Pvt. Ltd., a startup based in Mumbai, India, repurposed an AI system, originally developed to detect tuberculosis, to assist with diagnosing and assessing COVID-19 cases by checking computer tomography (CT) lung scans for signs and severity of the disease (Olson, 2020). A team led by the head of radiology, Francesco De Cobelli, at San Raffaele Hospital in Milan, Italy, immediately found the system made the disease look worse than it was. However, this AI application is in the early stages of development. Dr. De Cobelli’s team spoke daily with engineers from Qure.ai, who retrained the system using hundreds of X-rays of COVID-19 patients. Qure.ai CEO, Prashant Warier, said the early issues were resolved and that San Raffaele Hospital is now a paying customer. By comparison, it has taken five years to validate AI systems that can detect breast cancer. Skepticism remains as British radiologist and health-tech firm consultant Hugh Harvey commented, “There’s no way anyone has done that specifically for Covid in the past three months” (Olson, 2020, para. 6).